Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
Abstract:
Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
Information query
Patent Agency Ranking
0/0